Inventor · disambiguated record
Shawn Johnstone
Also filed as: JOHNSTONE SHAWN · JOHNSTONE SHAWN D · JOHNSTONE SHAWN DONALD
18 granted patents·24 pending applications·22 citations·filing 2004–2025
90Inventor score
Top patents by PatentIndex Score
42 records- 0194US10973805B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2020·Granted Apr 13, 2021·5 cites·20 claims
- 0291US11590111B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2021·Granted Feb 28, 2023·2 cites·10 claims
- 0390US11365186B2Substituted benzimidazoles, their preparation and their use as pharmaceuticalsEPIGENETIX INC·Filed 2020·Granted Jun 21, 2022·3 cites·10 claims
- 0487US11981657B2Substituted benzimidazoles, their preparation and their use as pharmaceuticalsEPIGENETIX INC·Filed 2022·Granted May 14, 2024·1 cites·20 claims
- 0585US10703740B2Substituted benzimidazoles, their preparation and their use as pharmaceuticalsNEOMED INST·Filed 2016·Granted Jul 7, 2020·3 cites·13 claims
- 0683US2025195480A1Macrocyclic azolopyridine derivatives as eed and prc2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0781US12109198B2Macrocyclic azolopyridine derivatives as EED and PRC2 modulatorsFULCRUM THERAPEUTICS INC·Filed 2022·Granted Oct 8, 2024·0 cites·5 claims
- 0879US7618993B2CompoundsASTRAZENECA AB·Filed 2006·Granted Nov 17, 2009·4 cites·10 claims
- 0977US10550089B2Inhibitors of protease-activated receptor-2HEPTARES THERAPEUTICS LTD·Filed 2017·Granted Feb 4, 2020·1 cites·7 claims
- 1077US2024425481A1Substituted benzimidazoles, their preparation and their use as pharmaceuticalsEPIGENETIX INC·Filed 2024·Application pending·0 cites
- 1176US7906654B2Benzimidazole derivativesASTRAZENECA AB·Filed 2007·Granted Mar 15, 2011·2 cites·2 claims
- 1274US2025214970A1Pyridinylacetamide derivatives as sodium channel activatorsXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1370US2025059189A1Pyridine derivatives and their use as sodium channel activatorsXENON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1469US10501459B2Substituted imidazo[1,2-a]pyridines as bromodomain inhibitorsNEOMED INST·Filed 2016·Granted Dec 10, 2019·1 cites·27 claims
- 1565US12054486B2Pyridine derivatives and their use as sodium channel activatorsXENON PHARMACEUTICALS INC·Filed 2022·Granted Aug 6, 2024·0 cites·35 claims
- 1665US10995072B2Inhibitors of protease-activated receptor-2HEPTARES THERAPEUTICS LTD·Filed 2019·Granted May 4, 2021·0 cites·13 claims
- 1764US2023203007A1Pyridinylacetamide derivatives as sodium channel activatorsXENON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1862US2024101531A1Pyridinamine derivatives and their use as potassium channel modulatorsXENON PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1959US2023121578A1Small molecule modulators of the btb domain of keap1MEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 2057US8168668B2CompoundsBESIDSKI YEVGENI·Filed 2009·Granted May 1, 2012·0 cites·18 claims
- 2155US2023416228A1Agents for the treatment of diseases by inhibition of foxo1FORKHEAD BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2254US11479539B2Small molecule modulators of the BTB domain of Keap1MEDIMMUNE LTD·Filed 2018·Granted Oct 25, 2022·0 cites·15 claims
- 2353US2009062251A1Novel Compounds 002ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2453US2011160180A1Cannabinoid Receptor LigandsASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2552US2024376111A1Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial diseaseMITOKININ INC·Filed 2022·Application pending·0 cites
- 2651US2025250276A1Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial diseaseMITOKININ INC·Filed 2025·Application pending·0 cites
- 2751US2020299262A1Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticalsNEOMED INST·Filed 2019·Application pending·0 cites
- 2851US2020299291A1Substituted imidazopyridines, their preparation and their use as pharmaceuticalsNEOMED INST·Filed 2019·Application pending·0 cites
- 2950US2023121952A1CompoundsINFLAZOME LTD·Filed 2021·Application pending·0 cites
- 3050US2023056273A1Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing sameDURECT CORP·Filed 2020·Application pending·0 cites
- 3149US2025129080A1Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial diseaseMITOKININ INC·Filed 2022·Application pending·0 cites
- 3246US8093402B2Benzimidazole derivativesBROWN WILLIAM·Filed 2011·Granted Jan 10, 2012·0 cites·20 claims
- 3345US2022162215A1Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial diseaseMITOKININ INC·Filed 2020·Application pending·0 cites
- 3444US10501438B2Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticalsNEOMED INST·Filed 2016·Granted Dec 10, 2019·0 cites·25 claims
- 3543US2006223868A1Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1)ASTRAZENECA AB·Filed 2004·Application pending·0 cites
- 3642US2024018146A1Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial diseaseMITOKININ INC·Filed 2021·Application pending·0 cites
- 3741US2016039842A1Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitorsEPIGENETIX INC·Filed 2014·Application pending·0 cites
- 3840US2008114041A1BenzothiazolesulfonamidesASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 3940US2008070946A1Hydroxymethylbenzothiazoles AmidesASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 4037US2022144826A1Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related DisordersCOLLABORATIVE MEDICINAL DEV LLC·Filed 2020·Application pending·0 cites
- 4136US10836742B2N-substituted bicyclic lactams, their preparation and their use as pharmaceuticalsNEOMED INST·Filed 2016·Granted Nov 17, 2020·0 cites·25 claims
- 4236US10472352B2Rac inhibitorsGeneyus LLC·Filed 2018·Granted Nov 12, 2019·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when Shawn Johnstone files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →